Nextcure Inc NXTC

$6.45 -0.33 (-4.87%)

Valuation

Market cap
29,534,000
Revenue TTM
$0
Net income TTM
$-55,840,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
30,800
Avg volume
75,404
Day's range
$6.43 – $6.96
Shares out
4,579,000
Stochastic %K
64%
Beta
1.22
Analysts
—
Price target
$20.00

Price

Company profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181...

Show more

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.

Industry
Biotechnology
Sector
Healthcare
Phone
240 399 4900
Website
https://www.nextcure.com
Address
2850 Quarry Lake Drive, Suite 280, Baltimore, United States

Latest news

Stocktwits

Aburose Nov 20, 11:00 PM
$NXTC Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) has announced the sale of its shares to Vertex Pharmaceuticals Incorporated for $85.00 per share in cash.
0 replies
Aburose Nov 20, 10:56 PM
$NXTC Compensation for each share—an excellent deal, provided the share price does not fall below twenty dollars.or 30 next monday the top
0 replies
Aburose Nov 20, 10:49 PM
$NXTC Will there be compensation for the company's shareholders, estimated at $23 per share?
0 replies
Aburose Nov 20, 10:41 PM
$NXTC Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
0 replies
Aburose Nov 20, 10:19 PM
$NXTC more voulme to go next monday the top
0 replies
Aburose Nov 20, 10:03 PM
$NXTC Just give me 12—I don’t need 15. It’s clear that the news holds no value for the company, given the lack of any real price increase.
0 replies
Aburose Nov 20, 9:57 PM
$NXTC buy and hold for next week the price under 20 still gold
0 replies
Aburose Nov 20, 9:56 PM
$NXTC NXTC has entered a new phase following the announcement of a definitive merger agreement with Avere Therapeutics—a deal that includes $320 million in funding to develop a once-weekly oral treatment targeting an inflammation-related pathway.
0 replies